These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 2404172

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
    Hanauer SB, Stathopoulos G.
    Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
    [Abstract] [Full Text] [Related]

  • 5. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG, Macdonald JK.
    Cochrane Database Syst Rev; 2012 Oct 17; 10():CD000543. PubMed ID: 23076889
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
    Kam L, Cohen H, Dooley C, Rubin P, Orchard J.
    Am J Gastroenterol; 1996 Jul 17; 91(7):1338-42. PubMed ID: 8677990
    [Abstract] [Full Text] [Related]

  • 9. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR, Mays DA.
    Ann Pharmacother; 1997 Jul 17; 31(7-8):907-13. PubMed ID: 9220055
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease.
    Wadworth AN, Fitton A.
    Drugs; 1991 Apr 17; 41(4):647-64. PubMed ID: 1711964
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
    Schroeder KW.
    Scand J Gastroenterol Suppl; 2002 Apr 17; (236):42-7. PubMed ID: 12408503
    [Abstract] [Full Text] [Related]

  • 15. Tolerability of aminosalicylates in inflammatory bowel disease.
    Ishaq S, Green JR.
    BioDrugs; 2001 Apr 17; 15(5):339-49. PubMed ID: 11437696
    [Abstract] [Full Text] [Related]

  • 16. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis.
    Sutherland LR, May GR, Shaffer EA.
    Ann Intern Med; 1993 Apr 01; 118(7):540-9. PubMed ID: 8095128
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update.
    Martin F.
    Dig Dis Sci; 1987 Dec 01; 32(12 Suppl):57S-63S. PubMed ID: 2891469
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.